Week in Review: ZAI Lab In-Licenses Two Sanofi Drug Candidates

ZAI Lab, a Shanghai novel drug startup led by Dr. Samantha Du, in-licensed two novel compounds from Sanofi for chronic respiratory diseases; Miraculins of Canada finalized an agreement for China distribution of its non-invasive diabetes screening device; TNI BioTech, a US company, and Hubei Qianjiang Pharma agreed on a plan to speed up development of their partnered immunotherapy; China-focused Cellular Biomedicine has made a series of announcements over the past two months that caused the company's stock to quadruple; Stryker will export trauma and spine medical devices from its China Trauson division to India next year; Celltrion, a Korean biotech, filed for US approval of a biosimilar to Remicade, a treatment for autoimmune diseases; and Pfizer reported that, in China trials, Lyrica was effective against post-shingles neuralgia, but not painful diabetic peripheral neuropathy. More details.... Stock Symbols: (NYSE: SNY) (TVE: MOM) (OTC: TNIB) (SHA: 600568) (NSDQ: CBMG) (NYSE: SYK) (KOSDAQ: 068270) (NYSE: PFE) Share this with colleagues: // //